Filing Flows › Sonoma Pharmaceuticals (SNOA) › Q1 FY26
Sonoma Pharmaceuticals (SNOA) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Aug 7, 2025
Sonoma Pharmaceuticals (SNOA) reported revenue of $4.0M for the first quarter fiscal 2026 (Q1 FY26), +18% from a year earlier and +7% from the quarter before. Operating margin was -27.3%, net loss $1.2M (30.9% of revenue).
Sonoma Pharmaceuticals, Q1 FY26: revenue $4.0M (+18% year over year), operating margin -27.3%, net loss $1.2M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.0M | +7% | +18% |
| Operating profit | −$1.1M | — | — |
| Net earnings | −$1.2M | — | — |
| Operating cash flow | −$2.0M | — | — |
What changed
Revenue was $4.0M in Q1 FY26, up 18% year over year and up 7% from the previous quarter.
Gross margin was 36.5%, down 2.1 points from a year earlier. Operating costs exceeded revenue by $1.1M, an operating margin of -27.3%. Operating expenses grew 3% against revenue growth of 18%. The fastest-growing cost line was Research & development (+26%). The quarter ended with a net loss of $1.2M, wider than the previous quarter's $776K loss.
Operating cash flow was −$2.0M. Non-cash charges added back $36K of depreciation and amortization and $57K of share-based compensation. Working capital and other items used $867K. Capital expenditures of $106K exceeded it, leaving free cash flow of −$2.1M.
Questions
What was Sonoma Pharmaceuticals' revenue in the first quarter fiscal 2026?
Sonoma Pharmaceuticals (SNOA) reported revenue of $4.0M for the first quarter fiscal 2026 (Q1 FY26), +18% from a year earlier and +7% from the quarter before.
Was Sonoma Pharmaceuticals profitable in the first quarter fiscal 2026?
Operating loss was $1.1M (-27.3% of revenue) and net loss $1.2M.